KC 11404

Drug Profile

KC 11404

Latest Information Update: 06 Dec 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kali-Chemie
  • Class Anti-inflammatories; Antiasthmatics; Piperazines; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Histamine H1 receptor antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Asthma

Most Recent Events

  • 30 May 2001 Profile reviewed but no significant changes made
  • 31 Aug 1998 No-Development-Reported for Asthma in Netherlands (unspecified route)
  • 14 Jun 1995 Preclinical development for Asthma in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top